When MedImmune won approval for its quadrivalent nasal flu vaccine back in February 2012, it kicked off the battle to claim a share of the next-generation influenza immunization market. Now, almost two years later, its parent company AstraZeneca has the race underway in Europe, too.
AstraZeneca ($AZN) snagged a contract in the U.K. that will make its Fluenz nasal spray the vaccine of choice for children ages two to 17.
Hemispherx Biopharma's RNA-based adjuvant, Ampligen (rintatolimod), is being tested in a new indication--this time intranasally for the first time in humans along with AstraZeneca's nasal flu vaccine FluMist.
The FDA has approved AstraZeneca's ($AZN) nasal FluMist Quadrivalent flu vaccine for use in people ages 2 to 49. Made at AstraZeneca's MedImmune unit, FluMist Quadrivalent contains two...
A study conducted by the Trudeau Institute finally demystifies how the nasal flu vaccine FluMist elicits protection. "Influenza infection normally induces a massive inflammatory response in the lungs
Flu vaccines would probably protect children better if they included both strains of influenza B instead of just one, Saint Louis University (SLU) researchers say. "Each year, the FDA selects two
Two new studies came out this week that could play a big role in shaping the market for seasonal flu vaccines. In the first, researchers found clear evidence that influenza is linked to a higher risk
The swine flu pandemic could make AstraZeneca's premium price for MedImmune look prescient. The drugmaker plans to produce 200 million doses of MedImmune's nasal-spray vaccine FluMist by March,
Anyone who still thinks that AstraZeneca paid too much when it offered a hefty premium for MedImmune's shares should check out a new report from Jefferies International, which estimates that the
Swine flu could be MedImmune's watershed moment. The company says it's gearing up to produce about five times as much H1N1 flu vaccine as it had expected, the New York Times reports. With